Product News from the May 6th MM&M News Brief

Share this article:

PRODUCT NEWS
The FDA yesterday approved GlaxoSmithKline's Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.

Amylin announced FDA approval of Byetta for treatment of patients with Type 2 diabetes. Byetta will be available by June 1, 2006, Amylin said.

The FDA has approved GlaxoSmithKline's Boostrix, the first combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria for adolescents.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.